Alembic Pharma Peer Comparison

NSE: APLLTD | BSE: 533573

₹794.85

₹12.05 (1.54%)

As on 29-Oct-2026IST

Market cap

₹15,630 Cr

Revenue (TTM)

₹7,784 Cr

P/E Ratio

22.5

P/B Ratio

2.7

Div. Yield

1.5 %

Edit

	Alembic Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Market cap (₹ Cr)	15,630	31,226	32,597	30,701	25,835
Revenue (₹ Cr)	7,784	3,564	1,593	9,779	1,936
Net Profit (₹ Cr)	688.47	414.00	438.64	-270.51	288.22
Net Margin (%)	8.77	11.23	27.16	-2.71	14.79
RoE (%)	14.02	8.38	25.02	-2.55	29.77
Price to Earnings	22.54	76.35	74.23	--	89.64
Price-To-Book	2.67	6.20	17.55	3.77	19.25

Income Statement (₹ Cr)

	Alembic Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Operating Revenue	7,783.95	3,564.00	1,592.52	9,778.62	1,935.80
Total Income	7,846.79	3,686.00	1,615.23	9,993.26	1,948.58
Total Expenditure	6,614.98	2,792.00	969.32	8,578.44	1,485.56
EBITDA	1,168.97	772.00	623.20	1,200.18	450.24
Depreciation	342.49	226.00	41.96	887.82	50.83
EBIT	826.48	546.00	581.24	312.36	399.41
Interest	97.71	217.00	4.21	347.94	40.84
Other Income	62.84	122.00	22.71	214.64	12.78
Exceptional Items	-66.99	12.00	0.00	-216.88	0.00
Profit before Tax	724.62	463.00	599.74	-37.82	371.35
Provision for Tax	36.15	49.00	161.10	232.69	83.14
Profit after Tax	688.47	414.00	438.64	-270.51	288.22

	Alembic Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Shareholder's Funds	5,674.81	4,940.00	1,857.45	8,142.24	1,288.82
Minority Interest	3.90	-5.00	0.51	0.55	0.00
Non-Current Liabilities	499.77	1,712.00	47.15	5,213.99	202.03
Current Liabilities	2,593.84	1,622.00	253.37	5,158.51	835.87
Total Liabilities	8,855.62	8,578.00	1,983.96	17,723.32	2,326.71

	Alembic Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Non-Current Assets	4,174.56	5,343.00	1,132.12	10,687.30	519.60
Current Assets	4,542.60	2,606.00	1,012.00	7,253.65	1,681.81
Total Assets	8,855.62	8,578.00	1,983.96	17,723.32	2,326.71
Total Debt*	1,360.85	2,125.00	26.49	5,495.48	259.37
Net Current Assets	1,948.76	984.00	758.64	2,095.14	845.94
Contingent Liabilities	160.39	768.26	17.25	95.72	19.09

	Alembic Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Cash From Operating Activities	782.73	390.00	292.17	1,652.60	205.05
Cash Flow from Investing Activities	-506.06	-241.00	-265.94	-826.03	-409.72
Cash from Financing Activities	-163.78	-54.00	4.10	-38.98	283.07
Net Cash Inflow / Outflow	112.89	95.00	30.33	787.59	78.39

	Alembic Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
ROCE (%)	11.74	6.79	32.42	1.24	29.22
ROE (%)	14.02	8.38	25.02	-2.55	29.77
ROA (%)	8.33	4.94	22.40	-1.56	24.77
EBIT Margin (%)	10.62	15.32	36.50	3.19	20.63
Net Margin (%)	8.77	11.23	27.16	-2.71	14.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Alembic Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Revenue Growth (%)	14.12	18.37	45.18	9.43	46.65
EBIT Growth (%)	7.41	252.26	115.51	-3.72	62.13
Net Profit Growth (%)	14.55	377.85	95.80	-199.34	89.49
EPS Growth (%)	30.14	1,001.33	63.29	-410.28	78.60
Book Value Growth (%)	9.32	13.47	26.03	0.33	144.31

	Alembic Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Price / Earnings	20.28	78.35	74.23	-147.63	88.26
Price / Book Value	2.67	6.20	17.55	3.77	19.25
Dividend Yield (%)	1.51	0.00	0.06	0.00	0.10
EV/EBITDA	14.36	42.34	51.99	29.03	57.19
Market Cap (₹ Cr)	13,008.55	19,071.62	20,944.75	18,108.89	12,753.19

	Alembic Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debt to Equity	0.02	0.31	0.02	0.55	0.11
Short term debt to equity ratio	0.21	0.09	0.00	0.09	0.05
Current Ratio	1.75	1.61	3.99	1.41	2.01
Quick Ratio	0.78	1.06	2.89	0.77	1.14
Interest Coverage	8.42	3.13	143.52	0.89	10.09

	Alembic Pharma	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debtors to sales (%)	18.84	16.50	22.50	23.05	26.28
Asset Turnover	0.94	0.43	0.81	0.56	1.66
Receivable days	36.70	58.75	88.98	78.20	40.13
Inventory Days	61.45	75.82	56.04	93.30	60.29
Payable days	157.72	186.21	99.95	226.14	232.47
Cash Conversion Cycle	-59.57	-51.64	45.07	-54.64	-132.04

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.